Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTGX POWR Grades
- PTGX scores best on the Value dimension, with a Value rank ahead of 53.78% of US stocks.
- PTGX's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- PTGX's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
PTGX Stock Summary
- PTGX's price/sales ratio is 49.08; that's higher than the P/S ratio of 94.5% of US stocks.
- With a year-over-year growth in debt of -66.49%, Protagonist Therapeutics Inc's debt growth rate surpasses just 5.05% of about US stocks.
- As for revenue growth, note that PTGX's revenue has grown 1,244.69% over the past 12 months; that beats the revenue growth of 99.15% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Protagonist Therapeutics Inc are FIXX, FULC, MEIP, GRTS, and RKDA.
- PTGX's SEC filings can be seen here. And to visit Protagonist Therapeutics Inc's official web site, go to www.protagonist-inc.com.
PTGX Stock Price Chart Interactive Chart >
PTGX Price/Volume Stats
| Current price | $39.64 | 52-week high | $40.46 |
| Prev. close | $33.84 | 52-week low | $14.16 |
| Day low | $33.58 | Volume | 864,300 |
| Day high | $40.46 | Avg. volume | 356,948 |
| 50-day MA | $30.47 | Dividend yield | N/A |
| 200-day MA | $24.85 | Market Cap | 1.74B |
Protagonist Therapeutics, Inc. (PTGX) Company Bio
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.
Latest PTGX News From Around the Web
Below are the latest news stories about Protagonist Therapeutics Inc that investors may wish to consider to help them evaluate PTGX as an investment opportunity.
Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that management will host an investor conference call and webcast to provide a brief corporate update and discuss data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera (PV), which was selected as an oral presentation at the European Hematology Association 2021 Annual Congress. The conference call will take place on Friday, June 11, 2021, at 8:00 a.m. EDT (14:00 CEST). |
Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia VeraProtagonist Therapeutics ("Protagonist" or "the Company") (Nasdaq: PTGX), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV) for the reduction of erythrocytosis in those patients who do not require further treatment for thrombocytosis and/or leukocytosis. Breakthrough Therapy Designation requires that the drug candidate |
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral interleukin-23 receptor (IL-23R) antagonist peptide. This study is designed to determine the safety, tolerability, and pharmacokinetics of PN-232 in healthy volunteers. Recruitment for the study is ongoing. |
2 ‘Strong Buy’ Momentum Stocks With Potential for Further GainsEvery rule has an exception, and a key to successful investing is knowing when to follow the rule – and when to follow the exception. So, while it’s true that past performance won’t ensure future gains, stocks that have shown strong and sustained gains, frequently show that past gains can build up a reliable momentum for further gains. The key is in the profile. Investors can look for stocks that offer a combination of two factors: strong, sustained gains and highly optimistic ratings from Wall Street’s analysts. Based on that profile, we’ve pulled up two stocks using TipRanks’ database. |
2 Momentum Stocks With Potential for Further GainsEvery rule has an exception, and a key to successful investing is knowing when to follow the rule – and when to follow the exception. So, while it’s true that past performance won’t ensure future gains, stocks that have shown strong and sustained gains, frequently show that past gains can build up a reliable momentum for further gains. The key is in the profile. Investors can look for stocks that offer a combination of two factors: strong, sustained gains and highly optimistic ratings from Wall Street’s analysts. Based on that profile, we’ve pulled up two stocks using TipRanks’ database. Both have shown great momentum in the past year, and amassed enough bullish calls from analysts to be given “Strong Buy” consensus ratings. Let's take a closer look. Protagonist Therapeutics (PTGX) We’l... |
PTGX Price Returns
| 1-mo | 30.10% |
| 3-mo | 28.58% |
| 6-mo | 100.61% |
| 1-year | 144.99% |
| 3-year | 461.47% |
| 5-year | N/A |
| YTD | 96.63% |
| 2020 | 185.96% |
| 2019 | 4.75% |
| 2018 | -67.64% |
| 2017 | -5.41% |
| 2016 | N/A |
Loading social stream, please wait...